Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $20.25 Average Price Target from Analysts
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month […]
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month […]
